Halaven (Eribulin mesylate) for Breast Cancer

Overview
Halaven is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic breast cancer in adults who have previously received two chemotherapy regimens. Halaven may be also referred to by its drug name, eribulin mesylate.

Halaven is a microtubule inhibitor. Halaven is believed to fight breast cancer by interfering with the ability of cancer cells to divide.

How do I take it?
Halaven is generally administered intravenously on Days 1 and 8 of a 21-day cycle.

Halaven comes in the form of an injectable suspension.

Side effects
The FDA-approved label for Halaven lists common side effects including low white blood cell count (neutropenia), low red blood cell count (anemia), weakness or tiredness, hair loss (alopecia), nausea, and constipation

Rare but serious side effects listed for Halaven include changes in your heartbeat (QT elongation).

For more details about this treatment, visit:

Halaven — Eisai
https://www.halaven.com/metastatic-breast-cancer

Halaven — BreastCancer.org
https://www.breastcancer.org/treatment/druglist...